Amgen Management

Management criteria checks 3/4

Amgen's CEO is Bob Bradway, appointed in May 2010, has a tenure of 13.58 years. total yearly compensation is $21.40M, comprised of 8% salary and 92% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth CHF142.11M. The average tenure of the management team and the board of directors is 5.6 years and 8.2 years respectively.

Key information

Bob Bradway

Chief executive officer

US$21.4m

Total compensation

CEO salary percentage8.0%
CEO tenure13.6yrs
CEO ownership0.1%
Management average tenure5.6yrs
Board average tenure8.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Bob Bradway's remuneration changed compared to Amgen's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2023n/an/a

US$8b

Jun 30 2023n/an/a

US$8b

Mar 31 2023n/an/a

US$8b

Dec 31 2022US$21mUS$2m

US$7b

Sep 30 2022n/an/a

US$7b

Jun 30 2022n/an/a

US$7b

Mar 31 2022n/an/a

US$6b

Dec 31 2021US$22mUS$2m

US$6b

Sep 30 2021n/an/a

US$6b

Jun 30 2021n/an/a

US$6b

Mar 31 2021n/an/a

US$7b

Dec 31 2020US$20mUS$2m

US$7b

Sep 30 2020n/an/a

US$7b

Jun 30 2020n/an/a

US$7b

Mar 31 2020n/an/a

US$8b

Dec 31 2019US$20mUS$2m

US$8b

Sep 30 2019n/an/a

US$8b

Jun 30 2019n/an/a

US$8b

Mar 31 2019n/an/a

US$8b

Dec 31 2018US$19mUS$2m

US$8b

Sep 30 2018n/an/a

US$2b

Jun 30 2018n/an/a

US$2b

Mar 31 2018n/an/a

US$2b

Dec 31 2017US$17mUS$2m

US$2b

Sep 30 2017n/an/a

US$8b

Jun 30 2017n/an/a

US$8b

Mar 31 2017n/an/a

US$8b

Dec 31 2016US$17mUS$2m

US$8b

Compensation vs Market: Bob's total compensation ($USD21.40M) is above average for companies of similar size in the Swiss market ($USD6.38M).

Compensation vs Earnings: Bob's compensation has been consistent with company performance over the past year.


CEO

Bob Bradway (60 yo)

13.6yrs

Tenure

US$21,399,733

Compensation

Mr. Robert A. Bradway, also known as Bob, has been the Chief Executive Officer of Amgen Inc. since May 23, 2012 and has been its President since May 2010. Mr. Bradway is responsible for the Amgen's global...


Leadership Team

NamePositionTenureCompensationOwnership
Robert Bradway
Chairman13.6yrsUS$21.40m0.11%
CHF 142.1m
Peter Griffith
Executive VP & CFO3.9yrsUS$7.07m0.0032%
CHF 4.1m
Esteban Santos
Executive Vice President of Operations7.4yrsUS$6.72m0.0099%
CHF 12.5m
David Reese
Executive Vice President of Research & Development5.9yrsUS$7.33m0.0078%
CHF 9.9m
Murdo Gordon
Executive VP of Global Commercial Operations5.3yrsUS$7.72m0.0059%
CHF 7.4m
Matthew Busch
Chief Accounting Officer & VP of Financeless than a yearno data0.00047%
CHF 595.8k
Mike Zahigian
Senior VP & Chief Information Officer4.9yrsno datano data
Arvind Sood
Vice President of Investor Relations19.3yrsno datano data
Jonathan Graham
Executive VP8.4yrsUS$7.24m0.0032%
CHF 4.0m
Nancy Grygiel
Senior VP of Worldwide Compliance & Business Ethics and Chief Compliance Officer3.9yrsno data0.0015%
CHF 1.9m
Derek Miller
Senior Vice President of Human Resources1.9yrsno data0.00095%
CHF 1.2m
Gilles Marrache
Senior VP & Regional GM7.9yrsno datano data

5.6yrs

Average Tenure

55.5yo

Average Age

Experienced Management: 000907582's management team is seasoned and experienced (5.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Robert Bradway
Chairman12.2yrsUS$21.40m0.11%
CHF 142.1m
Ronald Sugar
Independent Director13.4yrsUS$380.82kno data
Robert Eckert
Lead Independent Director11yrsUS$419.77k0.0013%
CHF 1.7m
Amy Miles
Independent Director3.4yrsUS$359.81k0.000080%
CHF 101.4k
Charles Holley
Independent Director6.8yrsUS$369.77k0.00024%
CHF 304.2k
Greg Garland
Independent Director10.2yrsUS$379.77k0.0020%
CHF 2.5m
Ellen Kullman
Independent Director7.2yrsUS$359.91k0.000080%
CHF 101.4k
Brian Druker
Independent Director5.6yrsUS$359.77kno data
Tyler Jacks
Independent Director11.6yrsUS$359.77k0.00051%
CHF 646.5k
Wanda Austin
Independent Director6yrsUS$359.77k0.00091%
CHF 1.2m
R. Williams
Independent Director9.2yrsUS$359.94k0.00099%
CHF 1.3m
S. Ishrak
Independent Director2.4yrsUS$359.89k0.00017%
CHF 215.5k

8.2yrs

Average Tenure

67yo

Average Age

Experienced Board: 000907582's board of directors are considered experienced (8.2 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/12/03 17:26
End of Day Share Price 2023/09/05 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Amgen Inc. is covered by 62 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Brian SkorneyBaird
Ishan MajumdarBaptista Research